Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors

Biochemical Pharmacology

Volumn 66, Issue 6, 2003, Pages 897-906

  Sasakawa, Yuka ^a   Naoe, Yoshinori ^a   Noto, Takahisa ^a   Inoue, Takeshi ^a   Sasakawa, Tatsuya ^a   Matsuo, Masahiko ^a   Manda, Toshitaka ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

ACHN; bFGF; FK228; Histone deacetylase inhibitor; PC 3; VEGF

Indexed keywords

ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; DEPSIPEPTIDE; FR 901228; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; MESSENGER RNA; PROTEIN SUBUNIT; VASCULOTROPIN;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER CELL; CELL HYPOXIA; CELL STRAIN; CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMPLANTATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; XENOGRAFT;

EID: 0042261694     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00411-8     Document Type: Article

References (46)

1. Ueda H., Nakajima H., Hori Y., Fujita T., Nishimura M., Goto T., Okuhara M. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J. Antibiot. 47:1994;301-310.
2. Shigematsu N., Ueda H., Takase S., Tanaka H., Yamamoto K., Tada T. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J. Antibiot. 47:1994;311-314.
3. Ueda H., Manda T., Matsumoto S., Mukumoto S., Nishigaki F., Kawamura I., Shimomura K. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot. 47:1994;315-323.
4. Byrd J.C., Shinn C., Ravi R., Willis C.R., Waselenko J.K., Flinn I.W., Dawson N.A., Grever M.R. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood. 94:1999;1401-1408.
5. Nakajima H., Kim Y.B., Terano H., Yoshida M., Horinouchi S. FR 901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241:1998;126-133.
6. Huang L., Pardee A.B. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med. 6:2000;849-866.
7. Kosugi H., Towatari M., Hatano S., Kitamura K., Kiyoi H., Kinoshita T., Tanimoto M., Murate T., Kawashima K., Saito H., Naoe T. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia. 13:1999;1316-1324.
8. Ferrara F.F., Fazi F., Bianchini A., Padula F., Gelmetti V., Minucci S., Mancini M., Pelicci P.G., Lo Coco F., Nervi C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61:2001;2-7.
9. Kim M.S., Kwon H.J., Lee Y.M., Baek J.H., Jang J.E., Lee S.W., Moon E.J., Kim H.S., Lee S.K., Chung H.Y., Kim C.W., Kim K.W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7:2001;437-443.
10. Goh M., Chen F., Paulsen M.T., Yeager A.M., Dyer E.S., Ljungman M. Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells. Neoplasia. 3:2001;331-338.
11. Kwon H.J., Kim M.S., Kim M.J., Nakajima H., Kim K.W. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer. 97(20):2002;290-296.
12. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:1995;27-31.
13. Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S. Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Lett 2003;195(2):161-8.
14. Sasakawa Y., Naoe Y., Inoue T., Sasakawa T., Matsuo M., Manda T., Mutoh S. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem. Pharmacol. 64:2002;1079-1090.
15. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS. 79:1997;1-8.
16. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 16:1996;4604-4613.
17. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
18. Huang L.E., Arany Z., Livingston D.M., Bunn H.F. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J. Biol. Chem. 271:1996;32253-32259.
19. Richon V.M., Sandhoff T.W., Rifkind R.A., Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10014-10019.
20. Sambucetti L.C., Fischer D.D., Zabludoff S., Kwon P.O., Chamberlin H., Trogani N., Xu H., Cohen D. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274:1999;34940-34947.
21. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:1990;4-6.
22. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol 1996;136:167-90.
23. Asplin I.R., Wu S.M., Mathew S., Bhattacharjee G., Pizzo S.V. Differential regulation of the fibroblast growth factor (FGF) family by alpha(2)-macroglobulin: evidence for selective modulation of FGF-2-induced angiogenesis. Blood. 97:2001;3450-3457.
24. Goto F., Goto K., Weindel K., Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab. Invest. 69:1993;508-517.
25. Pepper M.S., Ferrara N., Orci L., Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. 189:1992;824-831.
26. Seghezzi G., Patel S., Ren C.J., Gualandris A., Pintucci G., Robbins E.S., Shapiro R.L., Galloway A.C., Rifkin D.B., Mignatti P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol. 141:1998;1659-1673.
27. Pepper M.S., Mandriota S.J. Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells. Exp. Cell Res. 241:1998;414-425.
28. Compagni A., Wilgenbus P., Impagnatiello M.A., Cotten M., Christofori G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 60:2000;7163-7169.
29. Mie Lee Y., Kim S.H., Kim H.S., Jin Son M., Nakajima H., Jeong Kwon H., Kim K.W. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem. Biophys. Res. Commun. 300:2003;241-246.
30. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14:2000;34-44.
31. Krieg M., Haas R., Brauch H., Acker T., Flamme I., Plate K.H. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 19:2000;5435-5443.
32. Ko S.C., Gotoh A., Thalmann G.N., Zhau H.E., Johnston D.A., Zhang W.W., Kao C., Chung L.W. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum. Gene Ther. 7:1996;1683-1691.
33. Siemeister G., Weindel K., Mohrs K., Barleon B., Martiny-Baron G., Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56:1996;2299-2301.
34. Gnarra J.R., Zhou S., Merrill M.J., Wagner J.R., Krumm A., Papavassiliou E., Oldfield E.H., Klausner R.D., Linehan W.M. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. U.S.A. 93:1996;10589-10594.
35. Iliopoulos O., Levy A.P., Jiang C., Kaelin W.G. Jr., Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. U.S.A. 93:1996;10595-10599.
36. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., Abraham J.A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266:1991;11947-11954.
37. Emiliani S., Fischle W., Van Lint C., Al-Abed Y., Verdin E. Characterization of a human RPD3 ortholog, HDAC3. Proc. Natl. Acad. Sci. U.S.A. 95:1998;2795-2800.
38. Turner B.M. Decoding the nucleosome. Cell. 75:1993;5-8.
39. Lee D.Y., Hayes J.J., Pruss D., Wolffe A.P. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell. 72:1993;73-84.
40. Xiao H., Hasegawa T., Isobe K. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J. Cell Biochem. 73:1999;291-302.
41. Sowa Y., Orita T., Minamikawa S., Nakano K., Mizuno T., Nomura H., Sakai T. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem. Biophys. Res. Commun. 241:1997;142-150.
42. Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 87:1996;953-959.
43. Bannister A.J., Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 384:1996;641-643.
44. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 389:1997;349-352.
45. Thorne A.W., Kmiciek D., Mitchelson K., Sautiere P., Crane-Robinson C. Patterns of histone acetylation. Eur. J. Biochem. 193:1990;701-713.
46. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature. 403:2000;41-45.